Eric Mark Green - May 7, 2024 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)

Role
President, CEO and Board Chair, Director
Signature
/s/ Luis Cantarero
Stock symbol
WST
Transactions as of
May 7, 2024
Transactions value $
-$19,782,550
Form type
4
Date filed
5/9/2024, 03:38 PM
Previous filing
May 8, 2024
Next filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WST Common Stock Options Exercise $535K +9.32K +6.09% $57.38 162K May 7, 2024 Direct F1
transaction WST Common Stock Options Exercise $900K +15.7K +9.67% $57.38 178K May 7, 2024 Direct F1
transaction WST Common Stock Options Exercise $2.45M +41K +23.05% $59.64 219K May 7, 2024 Direct F1
transaction WST Common Stock Sale -$3.42M -9.32K -4.25% $366.64 210K May 7, 2024 Direct F1, F2
transaction WST Common Stock Sale -$5.75M -15.7K -7.48% $366.66 194K May 7, 2024 Direct F1, F2
transaction WST Common Stock Sale -$15M -41K -21.14% $366.65 153K May 7, 2024 Direct F1, F2
transaction WST Common Stock Options Exercise $537K +9K +5.89% $59.64 162K May 7, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WST Stock Option (Right to Buy) Options Exercise $0 -9.32K -100% $0.00* 0 May 7, 2024 Common Stock 9.32K $57.38 Direct
transaction WST Stock Option (Right to Buy) Options Exercise $0 -15.7K -100% $0.00* 0 May 7, 2024 Common Stock 15.7K $57.38 Direct
transaction WST Stock Option (Right to Buy) Options Exercise $0 -41K -47.27% $0.00 45.7K May 7, 2024 Common Stock 41K $59.64 Direct
transaction WST Stock Option (Right to Buy) Options Exercise $0 -9K -19.68% $0.00 36.7K May 7, 2024 Common Stock 9K $59.64 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.
F2 The price reported in Column 4 is a weighted average price.